Forward Pharma A/S

Forward Pharma A/S, incorporated on July 1, 2005, is a clinical-stage biopharmaceutical company. The Company is engaged in the development of FP187, a formulation of dimethyl fumarate (DMF) for the treatment of several inflammatory and neurological indications, including multiple sclerosis (MS). The Company’s clinical candidate, FP187, is under development for the treatment of relapsing remitting MS (RRMS) and other immune disorders, such as psoriasis.The Company’s DMF formulation, FP187, employs over two methods, which improves the release of DMF by reducing the peaks of monomethyl fumarate (MMF) in the bloodstream while maintaining overall DMF exposure levels, which, in turn, controls DMF’s side effects. FP187 uses an enteric coating material, which forms a polymeric barrier around each DMF-containing core tablet for the purpose of inhibiting the release of DMF in the stomach and allowing for release in the small intestine. Due to the enteric coating, the FP187 tablet remains intact in acid conditions, such as those found in the stomach but dissolves in a less acidic environment similar to the one found in the small intestine. 

Bank Name Forward Pharma A/S
Stock Exchange NASDAQ
Symbol FWP
Sector Healthcare
Industry Major Pharmaceuticals
Country United States
World Region America
CEO Dr. Claus Bo Svendsen
Employees 5
Registered Year 2005